25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Bluebird bio Inc
Buy, Hold or Sell?

Let's analyze Bluebird bio Inc together

I guess you are interested in Bluebird bio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bluebird bio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Bluebird bio Inc

I send you an email if I find something interesting about Bluebird bio Inc.

1. Quick Overview

1.1. Quick analysis of Bluebird bio Inc (30 sec.)










1.2. What can you expect buying and holding a share of Bluebird bio Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$1.77
Expected worth in 1 year
$4.82
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$3.05
Return On Investment
38.7%

For what price can you sell your share?

Current Price per Share
$7.87
Expected price per share
$5.8 - $13.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Bluebird bio Inc (5 min.)




Live pricePrice per Share (EOD)
$7.87
Intrinsic Value Per Share
$-44.91 - $86.47
Total Value Per Share
$-43.14 - $88.24

2.2. Growth of Bluebird bio Inc (5 min.)




Is Bluebird bio Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$194.5m$194.5m0.000.0%

How much money is Bluebird bio Inc making?

Current yearPrevious yearGrowGrow %
Making money-$211.9m-$211.9m0.000.0%
Net Profit Margin-718.4%-718.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Bluebird bio Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#253 / 932

Most Revenue
#210 / 932

Most Profit
#916 / 932

Most Efficient
#662 / 932
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Bluebird bio Inc?

Welcome investor! Bluebird bio Inc's management wants to use your money to grow the business. In return you get a share of Bluebird bio Inc.

First you should know what it really means to hold a share of Bluebird bio Inc. And how you can make/lose money.

Speculation

The Price per Share of Bluebird bio Inc is $7.87. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bluebird bio Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bluebird bio Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.77. Based on the TTM, the Book Value Change Per Share is $0.76 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.49 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bluebird bio Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.93-24.5%-1.93-24.5%-1.10-14.0%-5.65-71.8%-7.28-92.5%
Usd Book Value Change Per Share0.769.7%0.769.7%-1.49-18.9%-4.30-54.7%-1.67-21.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.516.4%0.253.2%
Usd Total Gains Per Share0.769.7%0.769.7%-1.49-18.9%-3.80-48.2%-1.42-18.1%
Usd Price Per Share8.34-8.34-1.38-13.98-56.06-
Price to Earnings Ratio-4.32--4.32--1.26--2.56--7.34-
Price-to-Total Gains Ratio10.94-10.94--0.93--4.42--14.98-
Price to Book Ratio4.71-4.71-1.37-2.53-2.92-
Price-to-Total Gains Ratio10.94-10.94--0.93--4.42--14.98-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.87
Number of shares127
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.51
Usd Book Value Change Per Share0.76-4.30
Usd Total Gains Per Share0.76-3.80
Gains per Quarter (127 shares)96.80-482.15
Gains per Year (127 shares)387.19-1,928.59
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10387377257-2186-1939
20774764514-4371-3868
3011621151771-6557-5797
40154915381028-8742-7726
50193619251285-10928-9655
60232323121542-13113-11584
70271026991799-15299-13513
80309830862056-17484-15442
90348534732313-19670-17371
100387238602570-21855-19300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.014.00.00.0%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%3.07.00.030.0%5.09.00.035.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%1.00.04.020.0%1.00.09.010.0%1.00.013.07.1%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%3.07.00.030.0%5.09.00.035.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Bluebird bio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7620.7620%-1.489+295%-4.302+664%-1.673+320%
Book Value Per Share--1.7711.7710%1.009+76%6.501-73%17.716-90%
Current Ratio--1.4081.4080%1.4080%2.508-44%6.697-79%
Debt To Asset Ratio--0.6860.6860%0.6860%0.525+31%0.356+93%
Debt To Equity Ratio--2.1832.1830%2.1830%1.419+54%0.826+164%
Dividend Per Share----0%-0%0.506-100%0.253-100%
Enterprise Value--713071500.000713071500.0000%-158598640.000+122%1064804838.600-33%3208616121.460-78%
Eps---1.930-1.9300%-1.099-43%-5.652+193%-7.284+277%
Ev To Ebitda Ratio---4.266-4.2660%inf+inf%inf+inf%inf+inf%
Ev To Sales Ratio--24.17424.1740%-5.377+122%74.256-67%150.823-84%
Free Cash Flow Per Share---2.223-2.2230%-1.266-43%-5.147+132%-6.279+183%
Free Cash Flow To Equity Per Share---0.436-0.4360%-0.248-43%-2.962+580%0.793-155%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--86.468--------
Intrinsic Value_10Y_min---44.908--------
Intrinsic Value_1Y_max---0.263--------
Intrinsic Value_1Y_min---5.891--------
Intrinsic Value_3Y_max--6.013--------
Intrinsic Value_3Y_min---16.599--------
Intrinsic Value_5Y_max--20.493--------
Intrinsic Value_5Y_min---26.021--------
Market Cap76513871.400-1097%915940500.000915940500.0000%266025360.000+244%1020658038.600-10%2737726821.460-67%
Net Profit Margin---7.184-7.1840%-7.1840%-48.918+581%-33.658+368%
Operating Margin---6.634-6.6340%--100%-44.751+575%-31.861+380%
Operating Ratio--9.2819.2810%10.418-11%51.593-82%39.767-77%
Pb Ratio4.443-6%4.7084.7080%1.367+244%2.534+86%2.921+61%
Pe Ratio-4.079+6%-4.322-4.3220%-1.255-71%-2.561-41%-7.338+70%
Price Per Share7.870-6%8.3408.3400%1.380+504%13.976-40%56.060-85%
Price To Free Cash Flow Ratio-3.541+6%-3.752-3.7520%-1.090-71%-2.552-32%-8.619+130%
Price To Total Gains Ratio10.326-6%10.94210.9420%-0.927+108%-4.420+140%-14.978+237%
Quick Ratio--1.1731.1730%0.111+957%3.449-66%10.539-89%
Return On Assets---0.342-0.3420%-0.3420%-0.492+44%-0.374+9%
Return On Equity---1.089-1.0890%-1.0890%-1.099+1%-0.711-35%
Total Gains Per Share--0.7620.7620%-1.489+295%-3.796+598%-1.421+286%
Usd Book Value--194537000.000194537000.0000%194537000.0000%462950000.000-58%882818100.000-78%
Usd Book Value Change Per Share--0.7620.7620%-1.489+295%-4.302+664%-1.673+320%
Usd Book Value Per Share--1.7711.7710%1.009+76%6.501-73%17.716-90%
Usd Dividend Per Share----0%-0%0.506-100%0.253-100%
Usd Enterprise Value--713071500.000713071500.0000%-158598640.000+122%1064804838.600-33%3208616121.460-78%
Usd Eps---1.930-1.9300%-1.099-43%-5.652+193%-7.284+277%
Usd Free Cash Flow---244103000.000-244103000.0000%-244103000.0000%-402469200.000+65%-377606600.000+55%
Usd Free Cash Flow Per Share---2.223-2.2230%-1.266-43%-5.147+132%-6.279+183%
Usd Free Cash Flow To Equity Per Share---0.436-0.4360%-0.248-43%-2.962+580%0.793-155%
Usd Market Cap76513871.400-1097%915940500.000915940500.0000%266025360.000+244%1020658038.600-10%2737726821.460-67%
Usd Price Per Share7.870-6%8.3408.3400%1.380+504%13.976-40%56.060-85%
Usd Profit---211913000.000-211913000.0000%-211913000.0000%-374347400.000+77%-398290300.000+88%
Usd Revenue--29497000.00029497000.0000%29497000.0000%63397400.000-53%47190100.000-37%
Usd Total Gains Per Share--0.7620.7620%-1.489+295%-3.796+598%-1.421+286%
 EOD+2 -6MRQTTM+0 -0YOY+18 -95Y+22 -1710Y+17 -22

3.3 Fundamental Score

Let's check the fundamental score of Bluebird bio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.079
Price to Book Ratio (EOD)Between0-14.443
Net Profit Margin (MRQ)Greater than0-7.184
Operating Margin (MRQ)Greater than0-6.634
Quick Ratio (MRQ)Greater than11.173
Current Ratio (MRQ)Greater than11.408
Debt to Asset Ratio (MRQ)Less than10.686
Debt to Equity Ratio (MRQ)Less than12.183
Return on Equity (MRQ)Greater than0.15-1.089
Return on Assets (MRQ)Greater than0.05-0.342
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Bluebird bio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.019
Ma 20Greater thanMa 508.410
Ma 50Greater thanMa 1008.115
Ma 100Greater thanMa 2009.138
OpenGreater thanClose7.850
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Bluebird bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Fundamental data was last updated by Penke on 2025-01-16 14:37:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Bluebird bio Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bluebird bio Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -718.4% means that $-7.18 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bluebird bio Inc:

  • The MRQ is -718.4%. The company is making a huge loss. -2
  • The TTM is -718.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-718.4%TTM-718.4%0.0%
TTM-718.4%YOY-718.4%0.0%
TTM-718.4%5Y-4,891.8%+4,173.4%
5Y-4,891.8%10Y-3,365.8%-1,526.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-718.4%-104.8%-613.6%
TTM-718.4%-211.9%-506.5%
YOY-718.4%-209.8%-508.6%
5Y-4,891.8%-354.1%-4,537.7%
10Y-3,365.8%-488.5%-2,877.3%
4.3.1.2. Return on Assets

Shows how efficient Bluebird bio Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bluebird bio Inc to the Biotechnology industry mean.
  • -34.2% Return on Assets means that Bluebird bio Inc generated $-0.34 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bluebird bio Inc:

  • The MRQ is -34.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -34.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-34.2%TTM-34.2%0.0%
TTM-34.2%YOY-34.2%0.0%
TTM-34.2%5Y-49.2%+15.0%
5Y-49.2%10Y-37.4%-11.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-34.2%-12.7%-21.5%
TTM-34.2%-13.0%-21.2%
YOY-34.2%-12.3%-21.9%
5Y-49.2%-13.6%-35.6%
10Y-37.4%-15.7%-21.7%
4.3.1.3. Return on Equity

Shows how efficient Bluebird bio Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bluebird bio Inc to the Biotechnology industry mean.
  • -108.9% Return on Equity means Bluebird bio Inc generated $-1.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bluebird bio Inc:

  • The MRQ is -108.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -108.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-108.9%TTM-108.9%0.0%
TTM-108.9%YOY-108.9%0.0%
TTM-108.9%5Y-109.9%+1.0%
5Y-109.9%10Y-71.1%-38.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-108.9%-16.8%-92.1%
TTM-108.9%-17.7%-91.2%
YOY-108.9%-16.2%-92.7%
5Y-109.9%-20.3%-89.6%
10Y-71.1%-21.2%-49.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Bluebird bio Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Bluebird bio Inc is operating .

  • Measures how much profit Bluebird bio Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bluebird bio Inc to the Biotechnology industry mean.
  • An Operating Margin of -663.4% means the company generated $-6.63  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bluebird bio Inc:

  • The MRQ is -663.4%. The company is operating very inefficient. -2
  • The TTM is -663.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-663.4%TTM-663.4%0.0%
TTM-663.4%YOY--663.4%
TTM-663.4%5Y-4,475.1%+3,811.7%
5Y-4,475.1%10Y-3,186.1%-1,289.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-663.4%-202.6%-460.8%
TTM-663.4%-321.1%-342.3%
YOY--227.9%+227.9%
5Y-4,475.1%-371.8%-4,103.3%
10Y-3,186.1%-506.0%-2,680.1%
4.3.2.2. Operating Ratio

Measures how efficient Bluebird bio Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.28 means that the operating costs are $9.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Bluebird bio Inc:

  • The MRQ is 9.281. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.281. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.281TTM9.2810.000
TTM9.281YOY10.418-1.137
TTM9.2815Y51.593-42.313
5Y51.59310Y39.767+11.826
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.2812.171+7.110
TTM9.2813.241+6.040
YOY10.4183.257+7.161
5Y51.5934.839+46.754
10Y39.7676.440+33.327
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Bluebird bio Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Bluebird bio Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.41 means the company has $1.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Bluebird bio Inc:

  • The MRQ is 1.408. The company is just able to pay all its short-term debts.
  • The TTM is 1.408. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.408TTM1.4080.000
TTM1.408YOY1.4080.000
TTM1.4085Y2.508-1.101
5Y2.50810Y6.697-4.188
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4083.626-2.218
TTM1.4083.858-2.450
YOY1.4084.600-3.192
5Y2.5085.917-3.409
10Y6.6976.136+0.561
4.4.3.2. Quick Ratio

Measures if Bluebird bio Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bluebird bio Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.17 means the company can pay off $1.17 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bluebird bio Inc:

  • The MRQ is 1.173. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.173. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.173TTM1.1730.000
TTM1.173YOY0.111+1.062
TTM1.1735Y3.449-2.276
5Y3.44910Y10.539-7.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1733.022-1.849
TTM1.1733.369-2.196
YOY0.1114.337-4.226
5Y3.4495.931-2.482
10Y10.5396.457+4.082
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Bluebird bio Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Bluebird bio Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bluebird bio Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.69 means that Bluebird bio Inc assets are financed with 68.6% credit (debt) and the remaining percentage (100% - 68.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bluebird bio Inc:

  • The MRQ is 0.686. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.686. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.686TTM0.6860.000
TTM0.686YOY0.6860.000
TTM0.6865Y0.525+0.160
5Y0.52510Y0.356+0.169
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6860.341+0.345
TTM0.6860.342+0.344
YOY0.6860.314+0.372
5Y0.5250.365+0.160
10Y0.3560.385-0.029
4.5.4.2. Debt to Equity Ratio

Measures if Bluebird bio Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bluebird bio Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 218.3% means that company has $2.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bluebird bio Inc:

  • The MRQ is 2.183. The company is just not able to pay all its debts with equity.
  • The TTM is 2.183. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.183TTM2.1830.000
TTM2.183YOY2.1830.000
TTM2.1835Y1.419+0.764
5Y1.41910Y0.826+0.592
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1830.390+1.793
TTM2.1830.429+1.754
YOY2.1830.383+1.800
5Y1.4190.441+0.978
10Y0.8260.493+0.333
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bluebird bio Inc generates.

  • Above 15 is considered overpriced but always compare Bluebird bio Inc to the Biotechnology industry mean.
  • A PE ratio of -4.32 means the investor is paying $-4.32 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bluebird bio Inc:

  • The EOD is -4.079. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.322. Based on the earnings, the company is expensive. -2
  • The TTM is -4.322. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.079MRQ-4.322+0.244
MRQ-4.322TTM-4.3220.000
TTM-4.322YOY-1.255-3.067
TTM-4.3225Y-2.561-1.761
5Y-2.56110Y-7.338+4.777
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.079-2.195-1.884
MRQ-4.322-2.710-1.612
TTM-4.322-3.253-1.069
YOY-1.255-3.335+2.080
5Y-2.561-6.423+3.862
10Y-7.338-6.851-0.487
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bluebird bio Inc:

  • The EOD is -3.541. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.752. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.752. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.541MRQ-3.752+0.211
MRQ-3.752TTM-3.7520.000
TTM-3.752YOY-1.090-2.662
TTM-3.7525Y-2.552-1.201
5Y-2.55210Y-8.619+6.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.541-3.003-0.538
MRQ-3.752-3.732-0.020
TTM-3.752-4.078+0.326
YOY-1.090-4.504+3.414
5Y-2.552-8.328+5.776
10Y-8.619-9.433+0.814
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Bluebird bio Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.71 means the investor is paying $4.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Bluebird bio Inc:

  • The EOD is 4.443. Based on the equity, the company is fair priced.
  • The MRQ is 4.708. Based on the equity, the company is fair priced.
  • The TTM is 4.708. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.443MRQ4.708-0.265
MRQ4.708TTM4.7080.000
TTM4.708YOY1.367+3.341
TTM4.7085Y2.534+2.174
5Y2.53410Y2.921-0.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.4431.902+2.541
MRQ4.7082.272+2.436
TTM4.7082.473+2.235
YOY1.3672.459-1.092
5Y2.5343.688-1.154
10Y2.9214.241-1.320
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Bluebird bio Inc.

4.8.1. Institutions holding Bluebird bio Inc

Institutions are holding 43.686% of the shares of Bluebird bio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30BlackRock Inc7.94250.00021544376715550.0101
2024-09-30Vanguard Group Inc5.38660.0001104740071727071.6766
2024-09-30Geode Capital Management, LLC2.40840.000246830421667713.6927
2024-09-30State Street Corp1.97580.00013841923433821.1421
2024-09-30FMR Inc1.27640.000124819651869038.1437
2024-09-30Avidity Partners Management LP0.83890.0432163114316311430
2024-09-30Millennium Management LLC0.82740.00041608793-3537860-68.741
2024-09-30Lion Point Capital, LP0.81171.82581578256900000132.6933
2024-09-30Northern Trust Corp0.78990.00011535856-79465-4.9195
2024-09-30Bank of America Corp0.7260.0001141174313128810.2532
2024-09-30ExodusPoint Capital Management, LP0.66690.0041129666812966680
2024-09-30Renaissance Technologies Corp0.54420.0008105817226666833.6913
2024-09-30Masters Capital Management LLC0.50140.024797500000
2024-09-30Morgan Stanley - Brokerage Accounts0.49830968942-63126-6.1165
2024-09-30Goldman Sachs Group Inc0.41410.000180519039773297.613
2024-09-30Two Sigma Advisers, LLC0.36670.0009713100-133100-15.7291
2024-09-30AQR Capital Management LLC0.34880.0005678248-656271-49.1766
2024-09-30JPMorgan Chase & Co0.31980621856-13895-2.1856
2024-09-30Palo Alto Investors, LLC0.31080.0408604260-4029091-86.9585
2024-09-30Dimensional Fund Advisors, Inc.0.31060.0001603874-144425-19.3004
Total 27.26521.942353015805-3462416-6.5%

4.9.2. Funds holding Bluebird bio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30Vanguard Total Stock Mkt Idx Inv3.0150.0001586246300
2024-11-30ACATIS Datini Valueflex Fonds A1.69710.15663300000270050.8251
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr1.64130.0011319139800
2024-10-31Fidelity Small Cap Index1.00280.00341949794-1396-0.0715
2024-11-30Fidelity Extended Market Index0.55530.0011079764-7118-0.6549
2024-11-30Vanguard Russell 2000 ETF0.46150.0026897343237592.7197
2024-11-30Schwab Small Cap Index0.2390.002746471100
2024-11-30JPM Thematics Genetic Thrps C2 dist USD0.23720.036461180-33513-6.7745
2024-09-30NT R2000 Value Index Fund - NL0.22910.007445389-7624-1.683
2024-09-30NT R2000 Index Fund - NL0.22640.0035440245-7901-1.763
2024-06-30Galileo - Biotech Innovation Fund S USD0.20021.008638927300
2024-11-30Fidelity Total Market Index0.19960.000238809000
2024-09-30Northern Trust Russell 2000 Value Index0.19710.007538321800
2024-09-30NT R2000 Value Index Fund - L0.19710.007438321800
2024-11-30iShares Russell 2000 Small-Cap Idx Instl0.19130.00337188300
2024-11-30SPDR® Russell 2000 US Small Cap ETF0.18240.0033547497395426.3374
2024-09-30NT R2000 Index Fund - DC - NL - 20.18130.0035352522-2104-0.5933
2024-12-31iShares Russell 2000 ETF2.70950.0031263419-1000-0.3782
2024-11-30Fidelity Series Total Market Index0.13220.000125712100
2024-11-30Nuveen Small Cap Blend Idx R60.12920.002625127100
Total 13.62461.25321487051+64062+0.3%

5.3. Insider Transactions

Insiders are holding 0.632% of the shares of Bluebird bio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-06Andrew ObenshainSELL1409.24
2024-12-10Andrew ObenshainSELL488.4
2024-02-05Andrew ObenshainSELL9318
2024-02-05Thomas J KlimaSELL13518
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. All numbers in thousands.

Summary
Total Assets619,161
Total Liabilities424,624
Total Stockholder Equity194,537
 As reported
Total Liabilities 424,624
Total Stockholder Equity+ 194,537
Total Assets = 619,161

Assets

Total Assets619,161
Total Current Assets281,685
Long-term Assets337,476
Total Current Assets
Cash And Cash Equivalents 221,755
Net Receivables 13,009
Inventory 22,919
Other Current Assets 24,002
Total Current Assets  (as reported)281,685
Total Current Assets  (calculated)281,685
+/-0
Long-term Assets
Property Plant Equipment 267,049
Goodwill 5,646
Intangible Assets 10,438
Long-term Assets Other 54,343
Long-term Assets  (as reported)337,476
Long-term Assets  (calculated)337,476
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities200,113
Long-term Liabilities224,511
Total Stockholder Equity194,537
Total Current Liabilities
Short-term Debt 105,907
Accounts payable 18,498
Other Current Liabilities 75,708
Total Current Liabilities  (as reported)200,113
Total Current Liabilities  (calculated)200,113
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)224,511
Long-term Liabilities  (calculated)0
+/- 224,511
Total Stockholder Equity
Common Stock1,905
Retained Earnings -4,260,328
Accumulated Other Comprehensive Income -1,796
Other Stockholders Equity 4,454,756
Total Stockholder Equity (as reported)194,537
Total Stockholder Equity (calculated)194,537
+/-0
Other
Cash and Short Term Investments 221,755
Common Stock Shares Outstanding 109,825
Liabilities and Stockholders Equity 619,161
Net Debt 108,571
Net Working Capital 81,572
Short Long Term Debt Total 330,326



5.2. Balance Sheets Structured

All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
> Total Assets 
30,918
69,322
224,390
556,739
1,002,337
1,118,122
1,900,567
2,242,844
1,727,424
1,781,252
593,795
554,902
619,161
619,161
619,161619,161554,902593,7951,781,2521,727,4242,242,8441,900,5671,118,1221,002,337556,739224,39069,32230,918
   > Total Current Assets 
29,980
67,784
211,987
479,989
523,965
724,214
1,614,302
1,418,997
1,152,174
1,215,537
336,520
199,488
281,685
281,685
281,685281,685199,488336,5201,215,5371,152,1741,418,9971,614,302724,214523,965479,989211,98767,78429,980
       Cash And Cash Equivalents 
25,604
67,011
206,279
347,845
164,269
278,887
758,505
402,579
327,214
317,705
161,160
113,006
221,755
221,755
221,755221,755113,006161,160317,705327,214402,579758,505278,887164,269347,845206,27967,01125,604
       Short-term Investments 
3,507
0
0
125,710
353,680
425,491
531,604
982,725
779,246
833,546
138,343
67,321
0
0
0067,321138,343833,546779,246982,725531,604425,491353,680125,710003,507
       Net Receivables 
0
0
693
1,913
0
8,542
3,112
13,931
12,826
2,372
11,389
10,787
22,211
13,009
13,00922,21110,78711,3892,37212,82613,9313,1128,54201,91369300
       Other Current Assets 
869
773
5,708
6,434
6,016
19,836
8,377
19,762
45,714
522,239
25,628
8,618
0
24,002
24,00208,61825,628522,23945,71419,7628,37719,8366,0166,4345,708773869
   > Long-term Assets 
938
1,538
12,403
76,750
478,372
393,908
286,265
823,847
575,250
565,715
257,275
355,414
337,476
337,476
337,476337,476355,414257,275565,715575,250823,847286,265393,908478,37276,75012,4031,538938
       Property Plant Equipment 
728
1,288
10,920
15,740
82,614
156,955
199,606
246,622
337,061
346,850
101,238
291,358
267,049
267,049
267,049267,049291,358101,238346,850337,061246,622199,606156,95582,61415,74010,9201,288728
       Goodwill 
0
0
0
13,128
13,128
13,128
13,128
13,128
13,128
13,128
5,646
5,646
5,646
5,646
5,6465,6465,6465,64613,12813,12813,12813,12813,12813,12813,128000
       Long Term Investments 
0
0
0
18,448
347,814
180,452
324,193
506,123
131,506
122,891
97,114
1,414
0
0
001,41497,114122,891131,506506,123324,193180,452347,81418,448000
       Intangible Assets 
0
0
0
28,219
24,456
20,694
16,931
13,169
14,326
10,041
5,644
4,868
10,438
10,438
10,43810,4384,8685,64410,04114,32613,16916,93120,69424,45628,219000
       Other Assets 
210
250
1,483
1,215
10,360
22,679
23,940
44,805
79,229
72,805
53,277
52,128
0
0
0052,12853,27772,80579,22944,80523,94022,67910,3601,2151,483250210
> Total Liabilities 
86,625
125,069
72,723
65,482
151,841
248,682
277,135
357,774
442,431
426,196
219,518
358,559
424,624
424,624
424,624424,624358,559219,518426,196442,431357,774277,135248,682151,84165,48272,723125,06986,625
   > Total Current Liabilities 
2,893
4,628
34,874
42,978
40,368
74,533
95,612
146,431
223,580
203,588
152,993
128,237
200,113
200,113
200,113200,113128,237152,993203,588223,580146,43195,61274,53340,36842,97834,8744,6282,893
       Short-term Debt 
653
1,599
4,902
14,174
24,561
50,181
1,051
1,424
20,175
9,711
46,304
88,248
0
105,907
105,907088,24846,3049,71120,1751,4241,05150,18124,56114,1744,9021,599653
       Short Long Term Debt 
0
0
0
0
61,901
120,140
155,800
0
0
0
0
0
0
0
0000000155,800120,14061,9010000
       Accounts payable 
1,793
2,173
4,359
2,954
6,334
13,664
12,873
17,831
42,995
13,811
25,883
14,867
18,498
18,498
18,49818,49814,86725,88313,81142,99517,83112,87313,6646,3342,9544,3592,1731,793
       Other Current Liabilities 
107
516
273
475
3,584
4,479
56,014
97,969
141,556
180,066
78,524
51,962
9,036
75,708
75,7089,03651,96278,524180,066141,55697,96956,0144,4793,584475273516107
   > Long-term Liabilities 
83,732
120,441
37,849
22,504
111,473
174,149
181,523
211,343
218,851
222,608
66,525
230,322
224,511
224,511
224,511224,511230,32266,525222,608218,851211,343181,523174,149111,47322,50437,849120,44183,732
       Long term Debt Total 
0
0
0
0
61,901
120,140
154,749
153,319
0
0
0
0
0
0
000000153,319154,749120,14061,9010000
       Other Liabilities 
1,329
601
37,156
20,591
49,572
54,009
26,774
58,024
48,039
54,611
93
0
0
0
0009354,61148,03958,02426,77454,00949,57220,59137,1566011,329
       Deferred Long Term Liability 
0
0
37,641
15,889
44,253
50,612
24,483
0
0
0
0
0
0
0
000000024,48350,61244,25315,88937,64100
> Total Stockholder Equity
-55,707
-55,747
151,667
491,257
850,496
869,440
1,623,432
1,885,070
1,284,993
1,355,056
374,277
196,343
194,537
194,537
194,537194,537196,343374,2771,355,0561,284,9931,885,0701,623,432869,440850,496491,257151,667-55,747-55,707
   Common Stock
2
3
239
323
369
407
494
547
554
665
711
830
0
1,905
1,905083071166555454749440736932323932
   Retained Earnings -4,260,328-4,260,328-3,986,503-3,719,925-2,900,547-2,281,852-1,498,808-913,808-577,674-314,167-147,384-98,675-73,354-63,442
   Accumulated Other Comprehensive Income 
1
-527
-1,454
-71
-2,291
-1,149
-4,205
-3,627
-1,893
-5,505
-2,911
-4,070
0
-1,796
-1,7960-4,070-2,911-5,505-1,893-3,627-4,205-1,149-2,291-71-1,454-5271
   Capital Surplus 
0
0
250,103
638,389
1,166,585
1,447,856
2,540,951
3,386,958
3,568,184
4,260,443
4,096,402
0
0
0
0004,096,4024,260,4433,568,1843,386,9582,540,9511,447,8561,166,585638,389250,10300
   Treasury Stock00000000000000
   Other Stockholders Equity 
7,732
15,267
27,167
638,389
1,166,585
1,447,856
2,540,951
3,386,958
3,568,184
4,260,443
4,096,402
4,185,988
0
4,454,756
4,454,75604,185,9884,096,4024,260,4433,568,1843,386,9582,540,9511,447,8561,166,585638,38927,16715,2677,732



5.3. Balance Sheets

All numbers in thousands.




5.4. Cash Flows

All numbers in thousands.




5.5. Income Statements

All numbers in thousands.